Pantheon Vision Secures $1.8M to Advance Development of Bioengineered Corneal Implants

Pantheon Vision has closed $1.8 million in a second tranche from KeraLink International (KLI) to further advance its corneal implant technology. 

The funding is the second Pantheon Vision has received from KLI—a previous $2.5 million investment brings its total funding to $4.3 million. The funds will be used to further develop Pantheon Vision’s bioengineered corneal implants.
 
“Corneal blindness affects over 13 million people worldwide but unfortunately has limited long-term solutions available, especially in underdeveloped countries,” KLI Board Vice Chairman Douglas J. Furlong, Esq., said. “Pantheon Vision’s approach to alternative solutions for corneal transplants is directly aligned with our mission and we are proud to support those efforts.”
 
Pantheon Vision is creating bioengineered corneal implants to raise the standard of eye care globally and reduce reliance on donated corneal tissue, which is often unavailable in low- and middle-income countries (LMICs). The company will engage the U.S. Food and Drug Administration (FDA) in the coming months to guide plans for global product development.
 
“The additional funding from KLI positions Pantheon Vision to advance our bioengineered corneal implants to treat corneal blindness,” Pantheon Vision President/CEO John Sheets stated. “We are grateful for the support from KLI, which shares our passion for finding alternative solutions for curing corneal blindness globally.”
 
KeraLink International Inc. (KLI) is a non-profit, 501(c)(3) organization focused on eradicating corneal blindness and ensuring the right to sight for people in low- and middle-income countries where corneal blindness persists. 

Pantheon Vision is an early-stage biotech company developing bioengineered corneal implants to improve corneal procedures and reduce the reliance on donor tissue to address corneal blindness in emerging and developed markets. The company was formed and received initial funding from KeraLink International to pursue its mission of eradicating corneal blindness globally, with a focus on LMICs.